Allouche Cyril 4
4 · Revance Therapeutics, Inc. · Filed Jan 23, 2019
Insider Transaction Report
Form 4
Allouche Cyril
Principal Financial Officer
Transactions
- Sale
Common Stock
2019-01-22$17.77/sh−625$11,106→ 4,000 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2019-01-22−625→ 6,875 totalExercise: $13.35Exp: 2026-10-30→ Common Stock (625 underlying) - Exercise/Conversion
Common Stock
2019-01-22$13.35/sh+625$8,344→ 4,625 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Allouche.
- [F2]The Option vests in accordance to the following schedule: 25% on the first anniversary of the vesting commencement date of October 31, 2016, and 1/48th vesting each month thereafter for the remaining three years, subject to Mr. Allouche's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.